Abstract: Papers published during 2001 -2002 on the synthesis and preparation of polymers and polymer-based devices and their applications are reviewed. Polymers for drug and gene delivery, gene therapy, controlled drug release, conjugation with peptides, proteins, and nucleotides, tissue engineering, bone repair and regeneration, coatings, wound dressing, artificial skin and other artificial organs are discussed.
Introduction
Advantages and opportunities provided by the use of polymeric materials for biomedical applications, as well as their characteristics, have been discussed in my previous review on this subject published in 1999 [1] . Specific aspects related to their synthesis and applications have been extensively investigated and the discussion of the results of such investigations was the subject of numerous review papers published in the recent years .
In view of the explosive growth in the number of recently published papers on this subject, I'm limiting the present general review of biomedical applications of polymers to papers published during the last two years (2001, 2002) . The structure and synthesis of novel polymeric systems will be described. Their applications for controlled drug release, implantation, and gene or drug delivery, gene therapy, tissue engineering, wound dressing, artificial organs, skins, coatings, and artificial bone restoration will be discussed. Standard procedures of macromolecular synthesis are also used for the preparation of specialty polymers for medical applications. There is also considerable interest in the application of the combinatorial approach for the preparation and screening of polymers suitable for biomedical applications [36] . The molecular imprinting technique is also emerging as promising methodology for the preparation of such materials [37] [38] [39] . Determination of biocompatibility and biodegradability must usually follow synthetic procedures.
Targeted drug delivery
Polymer-anticancer drug conjugates can be targeted to specific sites. The sitespecific delivery of a drug increases its concentration at the tumor site, while 1 decreasing its non-specific toxicity by lowering doses that have to be administered to achieve the required therapeutic effect. Dendrimers, a new class of polymeric micelle-like materials, were introduced seventeen years ago by Tomalia and his coworkers [40] . Due to their well-defined molecular architecture, size, and multiplicity of surface sites, some dendrimers proved to be suitable for biomedical applications [40c] . Water soluble, biocompatible, and biodegradable dendrimers conjugated with drugs provide excellent platforms for drug delivery targeted to specific sites. The introduction of functional groups at the periphery may be used for the introduction of targeting and imaging sites, as well as for the attachment of drugs to be delivered. Structures with reproducible, tunable characteristics can be obtained thanks to their stepwise controlled synthesis. Design, preparation, and biological evaluation of new polyester dendrons and dendrimers based on 2,2-bis(hydroxymethyl)propionic acid have recently been described by Frechet et al.
[41] The dendritic wedges can be joined by trishydroxyphenylmethane to form a polyester-type non-cytotoxic dendrimer, which is soluble in water when its polyhydroxylated surface is exposed as shown in Fig.1 . Three dendrons linked to the commercially available 3-arm poly(ethylene glycol) (PEG) star formed a biocompatible dendrimer 3SPP, which has been chosen as platform for the targeted delivery of the anticancer drug doxorubicin (DOX). The linkage between the polymeric carrier and the drug attached to its surface should be stable under normal physiologic conditions, but should easily be hydrolyzed in the proximity of the targeted site. The keto group of DOX could be used to form an acidlabile hydrazone linkage. For this purpose its hydroxyl groups at the surface of 3SPP have been activated by reaction with nitrochloroformate in pyridine. The 4-nitrophenol end group was displaced by reaction with tert-butyl carbazate in benzene in the presence of DMAP. Cleaving t-Boc deprotected attached hydrazine. It was then coupled with the HCl salt of doxorubicin to yield the anticancer drug, conjugated with the dendrimeric molecule by a hydrazone link (cf. Scheme 1).
Scheme 1. Formation of the 3SPP dendrimer and its conjugation with doxorubicin (by permission from ref. [41b])
In a test conducted in vivo in mice this conjugate did not significantly accumulate in any vital organs, and showed a circulation half life time of 72 min, in contradistinction to the distribution pattern of the free drug (half life time of c. 8 min). Moreover, it did not show any significant cytotoxicity and at pH 4.5 (pH value found in liposomes) released 60% of the free drug within 10 min. In view of the anatomic difference between normal and tumor tissue, which allows accumulation of large polymeric molecules in neoplastic cells, this result suggests that the new system is showing a promising path for the development of dendrimeric species as scaffolds for drug delivery to cancerous tissues. Polyamidoamine (PAMAm) dendrimers, which are currently commercially available, have been one of the first dendrimers to be tested as vectors for drug delivery.
Attachment of targeting and imaging sites to PAMAm as well as conjugation with methotrexate, an anti cancer drug, has recently been described [42] . However, it has been shown [43] that PAMAm dendrimers are homolytic and cytotoxic, when their periphery is also cationic. Nevertheless, conjugates of the linear and branched polyamidoamines are being tested as vectors for intracytoplasmic delivery [44] . Conjugation with acrylate groups at their periphery has been recently described [42c] . Though PAMAm dendrimers with their shell expanded by the anionic polymeric species seem to be non-toxic, their biodegradation products may be expected to be toxic. They were synthesized using piperazine, diethanolamine, and acryloyl chloride as building blocks.
Poly(ethylene oxide) (PEG) connected with aspartic acid dendrons was conjugated with the anticancer drug cytosine arabinose [1-(β-D-arabinofuranosyl)cytosine] (ara-C). Conjugation of the dendrons with the drug by PEG links seems to be preferable. Significantly higher tumor inhibition has been observed when much lower doses of the conjugated drug, than of the native one at its optimal level, have been administered. Moreover, their circulated lives are much longer, which leads to a controlled release of the drug. It is expected that such conjugates will be used therapeutically against a broad range of cancer types [45] .
The copolymer of N-(2-hydroxypropyl)methacrylamide (HPMA), conjugated with doxorubicin (DOX) via Gly,DL-Phe,L-Leu-Gly (GPLG) spacer, was connected at one of its ends with one of the NH 2 groups of the monoclonal antibody. The star-shaped conjugate had a much higher antitumor effect than analogous conjugates with different geometry, which were earlier investigated. It has been prepared by radical precipitation copolymerization in acetone, initiated by 2,2'-azoisobutyronitrile (AIBN) in the presence of 3-sulfanylpropionic acid as chain-transfer agent.
The terminal carboxylic groups of the copolymer were esterified by N-hydroxysuccinamide in dimethylformamide (DMF) and reacted with anti-Thy-1,2 in phosphate buffer at pH 7.3 -7.8 [46] . The anticancer drug camptothecin was conjugated with a watersoluble triblock copolymer consisting of three poly(methacrylate)s, amidated and hydroxylated in their side chains [47a] . The conjugated drug 'MAG-CPT' is shown in Fig. 2 
Thermally responsive systems
Thermally responsive polymers such as poly(N-isopropylmethacrylamide-co-acrylamide) joined to elastin-like polypeptide, in conjunction with selective heating of a solid tumor, were applied for targeting such tumors [48a] . The thermoresponsive polymer poly(N-isopropylacrylamide) shows also a lower critical solution temperature in the presence of certain salts. Therefore, salt concentration variations can be used instead of temperature variations to dissolve or not to dissolve the polymeric coating of compression coated tablets [48b].
The thermally responsive, silky elastine-like peptide (ELP) was synthesized, using the recombinant DNA method for the preparation of amino acid-based biopolymers. It was used as a carrier for the targeted delivery of therapeutics to solid tumors, which was enhanced by the localization of ELP-drug conjugates within the solid tumor heated by regional hyperthermia. Experiments in vivo indicating targeting solid tumors by ELPs were described [48c].
A temperature-responsive conjugate, soluble in water below its glass transition temperature, T g , but hydrophobically collapsing above, was synthesized by copolymerizing N-isopropylmethacrylamide with N-propylmethacrylamide and with 4-nitrophenyl N-methacryloyl glycinate. Its 4-nitrophenyl ester groups were reacted with hydrazine, which converted it into hydrazide. The system for targeted drug delivery was subsequently obtained by conjugating it with DOX via a pH-sensitive hydrazone link [48d].
The design and development of a polymer device, providing local drug therapy to the thermally ablated solid tumors, was described. A study revealed that both niosomes (vesicles self-assembled using non-ionic surfactants) and liposomes can become pHsensitive by anchoring a randomly alkylated IPAAm copolymer to their surface, and that liposomes attached to them improve the in vitro efficiency of cytosine arabinose [48e].
pH-sensitive niosomal and liposomal formulations containing copolymers of N-isopropylmethacrylamide (IPAAm) have been characterized with respect to their vesiclepolymer interactions, stability in human serum and pH-responsiveness. The binding between niosomes and the polymer was mainly due to hydrogen bonding. Under mildly acidic conditions they release rapidly their content [48f].
Temperature-sensitive liposomes are considered to be a promising tool for sitespecific targeting of drugs. Temperature-sensitization of liposomes has been achieved, as a result of temperature dependant interaction between liposome membrane and a polymer, by modifying liposomes with a temperature-sensitive drug [31] . New liposome-based temperature-sensitive drug delivery systems for solid tumors have been investigated [49] . Liposome size and long circulation promote accumulation in the tumor, which is increased by nearly two orders of magnitude when the tumor tissue is locally heated to 42°C. It releases significant amounts of the drug almost instantaneously when heated to the transition region but do not release it in unheated parts of the body. Stimulation of the site-specific liposomal drug delivery, using near-infrared sensitizers and two-photon excitation, is being investigated [50] . Polysaccharide-anchored liposomes are used for site-specific, bio-stable and liganddirected delivery systems [51] .
Synthetic polymer conjugates with peptides, proteins, and nucleotides
The potential of protein-and nucleotides-based materials to solve a complex delivery and therapeutic problem is generally acknowledged. Many current investigations are dealing with interactions between synthetic, man-made polymers, and proteins or nucleotides. Poly(propylacrylic acid) has been found to significantly enhance transfections in vitro of lipoplex formulations (liposome-DNA complexes) in cell cultures. Moreover, it is very effective in disruption of cell membranes at pH lower than 6.5. This may provide significant improvements in the in vivo efficacy of drugs, such as DNA, proteins and peptides, which are susceptible to be attacked by lysonomal enzymes. It also may enhance the release of drugs from the acidic endosomal compartment to the cytoplasm [52] .
Poly(ethylene glycol) (PEG) has been extensively used for the covalent modification of biological macromolecules. PEG-branched aspartic acid dendrons conjugated with the anticancer drug ara-C have been discussed in the previous section [45] . PEG connected with ara-C by alkoxyamides seems to provide the highest activity. Recognition and degradation by proteolytic enzymes is prevented by the covalent attachment of PEG to proteins and peptides (PEGylation). An increase in the size of the peptides reduces renal filtration of the conjugates [53, 54] .
Functional groups required for the attachment of proteins and peptides may be introduced during PEGylation. N-terminated conjugates of PEG with granulocytose colony stimulating factor (CSF) and with the recombinant human magacaryocyte growth and development factor (rHuMGDF) were prepared by reductive alkylation of proteins with mono-methoxy PEG aldehyde [55] .
Synthesis by the recombinant DNA technique of elastin-like polymers composed of repeated (Gly-Ala-Gly-Ala-Gly-Ser) and (Gly-Val-Gly-Val-Gly-Pro) units have been described. Their biocompatibility and their potential utility for controlled drug and gene delivery were discussed [48c,53] .
A conjugate of mono-methoxyPEG (mPEG) with the recombinant interferon α-2b(PEG-Intron) has been recently investigated and the structure of its isomers was characterized. PEG-Intron showed a serum half-life of 48 -72 h consistent with a once a week dose sufficient to maintain a clinically effective reduction of the hepatitis C virus (HCV). Moreover, the greatest anti-HCV effect has been achieved by combining PEG-Intron with ribavirin [56] .
The site-specific attachment of insulin to mPEG did not alter substantially its potency in vivo, while enhancing significantly its resistance to aggregation. PEGylation of insulin almost completely eliminated its immunogenicity, allergenicity, and antigenicity. Conjugates remained in the system longer than the unmodified insulin [57] .
Bioconjugation of adhesive peptides with water-soluble polymer modifier enhances anti-metastasis activity, and it is believed that it may facilitate therapeutic use [58] . The thiolation of polycarbofil (PCP), by covalent attachment of cysteamine to neutralized Na-PCP, was described. Mucoadhesive properties of the cysteamine-PCP conjugate were increased by a factor of 2.5, in comparison to those of the free polymer. The disintegration time in water of tablets based on cysteamine-PCP was 3.2 times longer than that of tablets based on PCP. It has been concluded that this conjugate is a promising excipient for various drug delivery systems and it is a potential candidate for various muscoadhesive applications [59] . Micelles loaded with up to 25% of the anticancer drug 'paclitaxel' have been prepared by the solution casting method using PEG-block-poly(D,L-lactide). This block copolymer was synthesized by ring opening polymerization of the D,L-lactide monomer in MePEG-2000, in the presence of stannous octanoate [61] .
A novel modality of drug targeting to tumors has been recently developed. It is based on local release of drugs encapsulated in polymeric micelles, which is triggered by focused ultrasound radiation. This modality utilizes the fact that, on the one hand, polymeric micelles stabilize cells against mechanical damage induced by ultrasound radiation, and on the other, they sensitize the multi-drug-resistant cells to the drug action [62] .
Nanoparticles for targeted drug delivery
Nanoparticles for targeted drug delivery to liver have been prepared by using a conjugate of galactose with lactobionic acid, which was conjugated with cholic acid through an amine-terminated PEG (cf. Fig. 3 ). In aqueous medium, this conjugate forms core-shell type nanoparticles in sizes ranging from 10 to 30 nm. Their critical association concentration was found to be 0.05 g/l. They could be loaded with a hydrophobic drug, which could be slowly released due to its crystallization [63] . 
Controlled drug release

Microparticles and nanoparticles for drug release and delivery
Polymeric nano/micro-particles may find applications in the delivery of drugs, vaccines, and proteins. This technology has also provided a method for controlling the rate of their release. End-modified poly(lactide-co-glycolide) (PLG) microparticles, loaded with DNA or with the IFF-1 growth factor, have been investigated as a possible delivery platform [64] . A few microns in size microspheres have also been prepared from poly(L-lactic acid) grafted with polyacrylamide (PAAm) by the emulsion evaporation method. High hydrophilicity is attributed to the presence of PAAm residues on their surface. It was suggested that they could be used for peroral and parenteral drug delivery [65] .
Paclitaxel was encapsulated in biodegradable PLG nanospheres. The nanospheres were fabricated by dissolving PLG and Paclitaxel in methylene chloride. Distilled water with a small amount of 1,2-dipalmitoylphosphatidyl choline was added, as emulsifier. The resulting emulsion was sonicated for 90 min and stirred overnight at room temperature to evaporate CH 2 Cl 2 . The product was freeze-dried. About 250 nm large PLG nanospheres, loaded with Paclitaxel, were obtained. Its release in vitro could last as long as 3 months at nearly constant rate, after the initial burst. Lipid, used as emulsifier, which coated the nanospheres, was responsible for this release profile [66] . Paclitaxel loaded PLG nanospheres smaller than 200 nm have been prepared by the interfacial deposition method [67a] .
The use of nanoparticles loaded with heparin for its oral delivery was investigated. They were prepared by exposing the water-in-oil-in-water emulsion of two biodegradable (PCL and PLG) and two non-biodegradable positively charged polymers (Eudragit RS and RL) (used alone or in combination) to UV radiation. The highest encapsulation efficiencies were observed when Eudragit took part in the formation of the polymeric matrix. These nanoparticles seem to be good candidates for the oral administration of heparin [67b].
Proteins and antigens were entrapped in nanoparticles assembled by ionic interaction between water-soluble anionically and cationically charged materials. The anionic core solution of 0.05% sodium alginate + 0.05% cellulose sulfate and 0.05% of ovalbumin (OVA) was introduced in the form of a mist and was captured by a solution containing 0.05% spermine-4HCl + 0.05% CaCl 2 + 0.15 ml/100 ml of 50% poly(methylene-co-guanidine) HCl plus 1% of the pluronic copolymer. The instantaneously formed particles were centrifuged, suspended in sterile water, vortexed, centrifuged, and again suspended and centrifuged. To control the permeability of the particles, their core could be crosslinked by addition of 10% or 20% polydextran aldehyde with respect to OVA for 50% or 100% crosslinking, respectively. A study of the release of OVA from the nanoparticles to the saline solution with 1% of NaCl showed that 40% and 14% have been released at 0% and 50% crosslinking, respectively, within a 24 h period [68a,b] .
Polymeric microparticles have been prepared by reverse-phase suspension polymerization of N-2-hydroxyethylaspartamid (HEA) and glycidyl methacrylate (GMA). The resulting copolymer was crosslinked by N,N'-dimethylacrylamide or by N,N'-ethylenebisacrylamide and loaded during and after the crosslinking process with 5-fluorouracil. An in vitro release study showed that the release rate depended not only on the structure and composition of the beads but also on a procedure adopted for the incorporation of the drug into the microparticles [68c].
Microparticles for sustained drug release have been prepared using bioerodible polyanhydrides such as poly[1,6-bis(p-carboxyphenoxy)hexane] (PCPH), poly(sebacic acid) (PSA), and their copolymer poly(CPH-co-SA). The surface of microspheres made from PCPH is very smooth, while that made from PSA is quite rough and porous. A large initial burst has been observed from PSPH, but little activity afterwards. The release from PSA was nearly zeroth order and it lasted for 8 days. The release profile from poly(CPH-co-SA) showed an initial small burst but subsequently exhibited a nearly zero-order release for a month [68d].
Release of human serum albumin encapsulated into biodegradable polymer microspheres was investigated in vitro [69a] . PLG microspheres were loaded with a linear DNA as a model. They showed an initial burst release followed by a prolonged gradual release. They could be useful as a release delivery system for DNA [69b].
Microspheres were prepared from PLG modified by extending its polylactic segment through linkage with 2,2'-bis(2-oxazoline). The more rapidly degraded poly(ester amide) was formed as result of this modification. The release of small drug molecules from such microspheres was much faster than from the non-modified PLG microspheres [70] .
Oral formulation based on PLG microparticles released antituberculous drugs in a sustained manner. It was stable in the acidic gastric environment, and released it within 20 days in the intestinal fluid [71] . Nanoparticles were prepared from poly(3-hydroxyoctanoate) with carboxylic groups in lateral chains, which was produced by chemical modification of unsaturated bacterial polyesters [72] .
Nimodipine release from micelles loaded with this drug was investigated. Micelles have been prepared from the triblock copolymer PCl-PEG-PCL with short PEG groups at both ends of poly(ε-caprolactone) (PCL) [73a] . The PCl/PEG ratio of copolymer was the main factor controlling micelle size, drug loading content, and drug release behaviour. Micelle size and drug loading content increased, while the drug release rate deceased with increasing weight fraction of PCL. Nanoparticles made of PCL and containing the anti-cancer drug tamoxifen were prepared by the solvent displacement method using the acetone/water system. It was concluded that such nanoparticle formulations might provide increased therapeutic benefit by delivering the drug in the vicinity of the estrogen receptor [73b].
Microparticles coated with cellulose acetate phthalate/cellulose acetate butyrate (CPB) were prepared by a modified solvent evaporation method. They were used for the controlled release of the drug nitrofurantoin (NTF). Suspension of the microparticles with NTF/CPB in the ratio 1.0/1.4/1.6 was tested for ulcerogenicity and bioavailability. The bioavailability of NTF in the particles was comparable to that of the non-coated drug, while ulceration of the gastric mucosa was diminished [74] .
TAn immuno-specific albumin conjugated with microspheres containing cisplatin and 5-fluorouracil has been targeted to tumor cells. It was found that they delivered drugs more effectively than the unconjugated microspheres [75] .
Polyether-anhydrides are of particular interest for drug release, due to excellent surface erosion properties of polyanhydrides and excellent biocompatibility of polyethers. Microparticles containing ether-anhydride copolymer, synthesized by melt polycondensation of sebacic anhydride and PEG prepolymers, were investigated as candidates for delivery and release of drugs in the lungs. Simulated intestinal and gastric fluids showed that after 8 h a larger amount was released to the intestinal solution (c. 93% as compared to c. 77% to the gastric solution). However, 99% was released to the former and 93% to the latter solution after 48 h. The drug release to both solutions seemed to follow a near zero-order pattern [76a] . Both polyanhydrides and polyesters are of interest as materials for drug delivery because of the erosibility of their surfaces and excellent compatibility [76b].
The degradation of aliphatic ester-anhydrides is much faster than that of aromatic ones. Aliphatic poly(ester anhydride)s were synthesized by reacting acetic anhydride with 1,4-cyclohexanedicarboxylic acid, subsequent esterification with ethylene glycol, 1,3-propanediol, 1,4-butanediol or 1,6-hexandiol followed by melt polycondensation. The resulting poly(ester anhydride)s poly(CHDA-XDO) are stable in anhydrous environment at room temperature. Their hydrolytic degradation involves a surface erosion mechanism. It is completed within 130 -320 h, depending on the diol used. The degradation period increases with increasing molecular weight of the diol. Drug release depends on its degradation and the diffusion characteristics of poly(CHDA-XDO). The in vitro drug delivery assays indicated that up to 95% of the drug is released in a stable fashion during 130 and 350 h, for poly(CHDA-EDO) (90:10) and poly(CHDA-HDO), respectively [76c].
The release and biodegradation of the antibiotic Norfloxacin, which was used against eye irritation, from surfactant-free PLG nanoparticles was investigated. The size of the nanoparticles depended on the solvent used for their preparation and the rate of their degradation was size-dependent [77] .
Thermo-and pH-responsive micelles
The anticancer drug adriamycin was loaded into the core of thermo-responsive micelles formed by a block copolymer of D,L-lactide obtained by its ring opening polymerization initiated with the terminal hydroxyl group of the thermo-sensitive poly(N-isopropylacrylamide-co-dimethylacrylamide). The size of the micelles and the amount of incorporated drug depended on the temperature of preparation in the dialysis process. When it was conducted at 20 -25°C, as much as 5 -6 wt.-% of adriamycin could be incorporated into the 50 -75 nm large micelles [78] .
Terminally and randomly alkylated polymers of N-isopropylacrylamide, modified by copolymerizing them with N-vinyl-2-pyrrolidone (VP), were used for the preparation of pH-responsive micelles. This modification improves the localization in tumors of the micelles and decreases their uptake by the mononuclear phagocyte system. It lowers the pH of the phase transition but does not affect the onset of their micellization. The cytotoxicity of these micelles loaded with the anticancer photosensitizer AlCl3-phthalocyanine was substantially lower than that of Cremophor EL. The investigators claim that the above described modification may provide a promising alternative for the formulation of poorly water-soluble phthalocyanines [79] .
Stimuli-responsive polymers for coatings and blends
Nasal drug formulations containing polyvinylacetal diethylaminoacetate have a low viscosity at pH 4, which facilitates their installation in the nasal cavity. However, upon administration, they form a gel on the mucous membranes by responding to the change in pH. The sol-gel transition enables controlled drug release [80] .
The lower critical solution temperature of thermoresponsive polymers, such as poly-(N-isopropylacrylamide), is decreased by addition of certain salts. Salt concentration variations may be used instead of temperature changes to make the polymer coating of compression-molded tablets soluble or insoluble. It was suggested that the time lag of drug release can be controlled by the type and the amount of salts incorporated into the coating of compression-molded tablets [48b].
Eudragit RS powder (ionic copolymer composed of thee different monomers, based on polymethacrylates) was blended with 10% of polyethylene glycol 400. This EPG blend has a T g at around the body temperature. After 30 days of aging, it reaches a constant value at c. 35°C. Within 6 h, EPG matrix tablets containing acetaminophen (AAP) release to water 40% of AAP at 36°C, 55% at 39°C, and 95% at 42°C [81a] .
Compressed excipient tablets were prepared from hydroxypropyl methacrylate, which was grafted onto hydroxypropyl starch and hydroxypropyl cellulose substrates, by the Ce(IV) redox initiation method and subsequently crosslinked with ethylene glycol dimethacrylate. White powders obtained after lyophilisation were compression molded with model drugs into tablets. Dissolution tests of the tablets showed that 60% to 80% of the drugs were released within 12 h [81b].
Ultrasound compaction of indomethacin/polyvinylpyrrolidine tablets improves the release of the drug. Hydrophobic matrix tablets containing PEGs have been employed in the controlled release of water-soluble drugs [82a] .
Higher molecular weight PEG swells to a greater extent and tends to form, upon hydration, a stronger gel, less susceptible to erosion. Erosion is enhanced, however, by the presence of additional soluble components and reduces the effectiveness of the polymer in controlling the release of a drug [82b]. Interpolymer (IP) complexes have been prepared by the template polymerization of acrylic acid (AA) in poly(vinyl pyrrolidone) (PVP) as template. The hydrogen bonds between the carboxylic groups of PAA and the carbonyl groups of PVP were responsible for the formation of the IP complexes. Changing the PVP/PAA ratios can control the adhesion force and the release rate from them. The release rate of ketoprofen from such IP complex was pH dependent. Below pH 4.75 (pK of PAA) it seemed to be mainly controlled by the rate of diffusion of the drug, but above pH 4.75 by dissolution of the complex [82c]. Solid dispersion of hydrophobic drugs in water-soluble carriers has also been considered as a way of controlling the rate of their release [82d].
Stimuli-responsive gels and micelles
Several stimulus-responsive 'smart' hydrogels have recently been described. These hydrogels respond to external or internal stimuli, which induce abrupt changes in the physical nature of the matrix. External stimuli may be due to changes in temperature or pH or ionic strength, to changes in concentration of a biomolecule or glucose, to electric current or to ultrasound radiation. Glucose-sensitive hydrogels were developed to monitor the release of insulin [83] .
Aqueous solutions of stimuli-sensitive polymers may be converted into gels by changes in the environmental conditions, such as temperature or pH. A hydrogel formed under physiological conditions, which maintains its integrity for the desired time-period, may provide various advantages over a conventional one. The pharmaceutical and biomedical uses of the sol-gel transition include controlled release, solubilization of hydrophobic drugs, cell immobilization, and delivery of proteins and genes. N-Isopropylamide copolymers, block copolymers of PEG with PLG, the pluronic triblock (PEG/PPO/PEG), certain inclusion complexes of PPG-grafted dextran, and of modified and unmodified natural polymeric systems, which may behave in this way, have been extensively investigated [84] .
PPG-grafted dextran (PPGD) was synthesized by reacting the amino-terminated PEG with hydroxyl groups of dextran. Hydrogels were obtained by preparing their inclusion complexes in β-cyclodextrines (βCDN). These hydrogels showed rapid gelation properties. Their gel-sol phase transition was due to the dissociation of the inclusion complexes. The temperature of this transition was dependent on the degree of grafting of PPG and the initial PPGD/βCDN ratio [85a] . Polyampholytes have been prepared by, UV induced, copolymerization of 2-(dimethylamino)ethyl methacrylate or methacryloyloxyethyltrimethylammonium chloride with an anionic monomer, such as acrylic acid. The pH-responsive swelling and the pH-and electro-responsive drug release of these copolymers were investigated. The cation-rich copolymer swelled in acidic solution and shrunk in alkaline, while an anion-rich copolymer showed a reverse behaviour. The polyampholyte interacted with ionic drugs by ionic binding and by physical adsorption [85b].
The poly(vinyl alcohol) (PVA)/chitosan interpenetrating polymer network (IPN) hydrogel was prepared by the UV-radiation method. It was electro-sensitive. Swollen PVA/ chitosan IPN bent in response to the applied electric field, when placed between a pair of electrodes. The bending angle and the bending speed rises with increasing applied voltage and concentration of NaCl [86] .
Biomolecule-sensitive hydrogels undergo swelling changes in response to a specific biomolecule. Glucose and enzyme sensitive hydrogels have been described. Molecular imprinting and the specific interactions involved in the synthesis of biomolecule sensitive hydrogels have been discussed [87] .
Pulsatile drug release and delivery is receiving increasing attention and two extensive reviews on this subject have been published during the last two years [30, 88] . A pulsatile release profile is characterized by a lag time followed by a rapid and complete drug release, at each step. Pulsatile systems may be either site-specific or time controlled.
Site-specific systems are controlled by environmental factors, while time-controlled systems are primarily controlled by the delivery systems themselves. For example, calcium alginate gel beads, 1 mm in diameter, were encapsulated by coats of a calcium binding, water soluble copolymer -poly(N,N-dimethylacrylamide-co-carboxyl-N-propylacrylamide). The thickness of the coats was changed in a few steps from about 30 µm to 125 µm. The diffusion of sodium ions converted calcium alginate into sodium alginate and caused its disintegration. Osmotic pressure accumulating inside the capsules busted them at times determined by the thickness of the coat [30b].
Fenofen (Fen) was not released in significant amount within 12 h from its conjugate with poly(α,β-(N-2-hydroxyethyl-DL-aspartamid) (PEHA) into simulated gastric and intestinal fluids. Its release was controlled by the hydrolysis of the ester bond between Fen and PEHA, which involved breakage of a sigma bond. The rate of the hydrolysis followed pseudo first-order kinetics [89a]. Spray dried formulations, containing sucrose and polysorbate 20, of Zn complexed recombinant human growth factor (rhGF), homogenized with the aqueous SABER system, consisting of sucrose acetate butyrate and PLA as a polymeric release modifier, have been investigated. The in vivo release of the rhGF SABER suspensions indicated that addition of 1% w/w of PLA to SABER reduced the initial release from 78% to less than 5% [89b]. was also formed when L-PLA was added to the solution. Slow release of insulin from these complexes was observed. Its rate could be controlled by changing the molecular weight of PLA, as well as by adding PLA-PEG copolymers [90a] .
ABA triblock copolymers consisting of hydrophilic PEG A-blocks and a hydrophobic PLG B-block are potentially useful for drug delivery systems and the controlled or site specific administration of proteins, oligonucleotides, and DNA. Their main advantage over PLG is their rapid swelling upon exposure to water, providing a friendly environment for such therapeutics. Differences in the release of proteins from the ABA copolymers and from that observed from PLG may probably be attributed to their physically crosslinked hydrogel morphology. However, the encapsulation of proteins into ABA nanospheres is yet to be accomplished. Moreover, the compatibility and stability of proteins with ABA copolymers must also be further explored [32] .
A poly(ethylene glycol)-based copolymer containing multiple thiol groups was crosslinked under mild conditions to form a polymer hydrogel. It seems to be particularly useful for the delivery of fragile therapeutics, such as proteins, since neither high temperature nor organic solvents are required for the formulation and patient administration processes [90b].
Complexes of histidylated polylysines with oligonucleotides (ODNs) and plasmids were investigated. The biological activity of antisense ODN was increased more than 20-fold when it was complexed with highly histidylated oligolysine into spherical cationic nanoparticles. Histidylated polylysine, which formed cationic particles with a plasmid, yielded 3 -4.5 orders of magnitude higher transfection than polylysine [91a] . Poly(L-lysine) and poly(L-arginine) were tested to determine the size of these polycationic peptides that could be administered without a cytotoxic effect. It has been concluded that they are cytotoxic at relatively high molecular weights (MWs), but their 14-mers (MWs of about 9000 Da) suppress mucin cells release without cytotoxicity [91b].
Synthesis, composition, and properties of the hydrogels
Hydrogels may be formed as a result of physical or chemical crosslinking of hydrophilic polymers and copolymers or of copolymers with hydrophilic segments. When their formation is due to molecular entanglement of polymeric chains or interactions due to ionic, pH-bonding, or hydrophobic interactions, they are called 'reversible' or 'physical'. They are called 'chemical' or 'permanent' when their formation is due to chemical crosslinking. Interaction, between a multifunctional ion and a polyelectrolyte of opposite charge, leads to formation of an 'ionotropic' hydrogel [33] . Physical gels may sometimes be preferred for biomedical applications, because residual amounts of the crosslinking agents may be cytotoxic. Some hydrogels may absorb up to thousand times of their weight in water. Their use for controlled drug release and for cell encapsulation is presently investigated. For such applications, biodegradability under physiological conditions is often required. The originally three-dimensional structure has to disintegrate into harmless products to ensure their good biocompatibility. The adverse effects that sometimes may be caused by chemical crosslinking can be avoided by using physically crosslinked gels [92a] . PVA was crosslinked to different degrees with ethylene glycol diglycidyl ether (ETDG) and substituted with 10% of oleoyl chloride (cf. Fig. 4) . Sustained release at 37°C into aqueous buffers of vanocomycin hydrochloride, used as model compound, was investigated. It was found that, after an initial 7.5 h period, the release is stable for at least 20 h. Less than 10% of vanocomycin was released from the gel, during this time period, when the PVA-ETDG10-OL10 gel was used [94] . Fig. 4 . Chemical structure of the PVA-ETDG-OL gels An IPN gel of PVA with vinyl terminated polydimethylsiloxane (PDMS) was prepared by adding PDMS mixed with 0.5 wt.-% of 2,2-dimethyl-2-phenylacetophenone and with 0.5 wt.-% of methylenebisacrylamide to a 10 wt.-% aqueous solution of PVA. The equilibrium water content of the hydrogels prepared with various PVA/PDMS ratios was, at pH 7, in the 52.5 -62.9% range [95] .
PVA with 11.15% of its hydroxyls esterified by maleic acid (M-PVA) was crosslinked by heating, due to the esterification of its free carboxyl groups by the hydroxyls of PVA. After crosslinking, a few carboxyl groups remained free. Tablets were prepared by pressing 75 -250 µm large grains at pressures ranging from 200 -600 kg/cm 2 . They could be loaded with p-acetamidophenol. At 37°C they released within 60 min ca. 95% of its content, when placed in a buffer solution at pH 7 [96] . PVA gels, prepared by crosslinking with glutaraldehyde, were loaded with theophylline. Their swelling by water depended on the degree of crosslinking. It was not affected by changes in the pH of the solution. Drug release followed a Fickian model [97a] . The release of theophylline from chitosan grafted with acrylamide was also investigated. The amount of theophylline released from the matrix tablets was controlled by relaxation of the polymeric structure and by the diffusion process [97b].
The release of gentamycin sulfate from IPN matrix hydrogels based on poly(acrylic acid) and gelatin, crosslinked with N,N'-bismethylenebisacrylamide and glutaraldehyde, was investigated. It was found that the rate of the release was faster when the concentration of gelatin in the IPN was higher and almost 85% of the loaded drug was released within 7 days [97c].
PVA modified with pendant ester-acrylate groups (cf. Fig. 5 ), was crosslinked via photopolymerization. Degradation of this gel proceeded through hydrolysis of the ester groups in the crosslinks. Increasing crosslinking density from 0.3 to 0.64 mol/L could increase the overall degradation time of these hydrogels from c. 12 to 45 days. Likewise, as a result of change in macromer concentration at the time of its crosslinking from 10% to 30%, its overall degradation time increased from about 1 to 35 days. The authors of this paper believe that the ability to tailor the polymeric network, of this class of hydrogels, to fit a wide range of degradation times and mass loss profiles, should make them attractive for a wide range of biomedical applications [98] . Cryotropic gelation processes proceed as a result of moderate freezing, followed by storing in the frozen state and subsequent thawing of solutions, or colloidal dispersions that contain polymeric and monomeric precursors. The polymeric materials formed under these conditions are called 'cryogels'. They are microporous heterophase gels. In the course of gel formation, crystals of the frozen solvent act as porogens [99] . Atactic poly(vinyl alcohol) hydrogel (a-PVA/NaCl/H2O) loaded with theophylline was gelled at -20 C. However, after storage at room temperature, it developed an unwanted crystalline structure, due to embedding of theophylline with a thin layer of the gel. This problem could be avoided by freezing it at -30°C for 16 h, followed by thawing at room temperature for 8 h. Samples prepared by repeating the above procedure for three times showed a more sustained release behaviour [100] .
Synthesis of new polymeric biodegradable pH-responsive hydrogels based on N-vinyl-2-pyrrolidone, sucrose monoacrylate, and acrylic acid was described. Freeradical polymerization, initiated by AIBN, was used for the preparation of these polymeric hydrogels. Bismethylenacrylamide was used as the crosslinking agent. Propanolol HCl (PPH) was entrapped, as a model drug, in the gels [101] .
A novel glucose-responsive gel formulation of carbomer gel was tested. Carbomer resin is a special case of nonlinear-branched polymer chains that interconnect to form a 3-dimensional network structure. To minimize leaching to the surroundings and prevent toxicity of the gel, it was stabilized via covalent coupling of the gel components, consisting of a specific polysaccharide, plant lectin, and concovalin A, to the carbomer resin. Amino groups on the lysine residue of concovalin were bonded with the carboxylic moieties on Carbopol ® 974P NF. Dextran in the formulation produced the glucose-responsive transformation from gel to sol in the presence of free glucose. Delivery of insulin, at 37°C, in response to the presence of glucose in the physiologically relevant concentration range was demonstrated for this carbomerstabilized gel [102] .
Biodegradable polypeptide hydrogels based on poly(L-glutamate) (PLG) as the polymer backbone and poly(ethylene glycol) dimethacrylate (PEG-DMA) as the crosslinker have been prepared by photopolymerization in phosphate buffer solution at pH 7.4. They were synthesized with different crosslinking densities by crosslinking PEG-MA-graft-PLG with PEG-DMA using equivalent amounts of methacrylate groups from both components. 2,2-Dimethoxy-2-phenylacetophenone was added as a promoter. Drug-loaded hydrogels were prepared by adding the drug to this solution before the onset of irradiation by UV light at 365 nm. The release in vitro at 37ºC of several model proteins was investigated. Rapid release during the first 16 h was relatively independent from the molecular weight (MW) of the protein. Afterwards, the release rates were influenced by their MWs as well as by the crosslinking density. For insulin, a small protein, the release from hydrogels with crosslinker ratios 10:1 and 5:1, was almost complete after 2.5 days [103] . Peroral delivery of the peptide drug 'octreotide' has been recently investigated using a novel superporous polymeric hydrogel [104] .
Gene therapy and delivery
The application of triblock copolymers PEG-b-poly(propylene oxide)-PEG (pluronic polymers) in gene therapy has recently been proposed. They are composed of two PEG hydrophilic blocks and one hydrophobic block (PPO). They can modify the biological response during gene therapy in the skeletal muscle by enhancing the transgene expression and the therapeutic effect of the transgene. They can also be used for gene and oligonuclotides delivery as polycation-conjugates (polyplexes) [105] .
The polycation polyethylamine (PEI) has been widely investigated as a delivery vehicle for DNA, especially in its branched form. PEI-mediated gene delivery is based on its electrostatic interactions with the negative phosphate groups of DNA. It involves condensation of DNA into compact particles that can be taken by the cells by natural processes such as adsorptive endocytosis, release from endosoms into cytoplasm and uptake of the DNA into the nucleus. Neutral complexes, which have a tendency to aggregate, are formed at N/P ratios of 2 to 3. Complexes with a strong positive net charge, which don't aggregate, are formed only at high N/P ratios. Their size and shape also depends on the experimental protocol of complex formation. Protection of these transfection complexes from non-specific interactions and increase in their target specificity and gene expression was investigated [106a] . Polymethacrylates containing tertiary amine, pyridine, imidazole and acidic groups, as well as polyamines containing PEG blocks or grafts were synthesized and their ability to act as vectors for drug delivery was found to depend on their molecular weight and composition [106b].
It seems that polycationic carrier molecules can be efficiently targeted to tumors via the blood stream to achieve predominant gene expression in tumor tissue. Therapeutic concepts based on suicide genes or cytokines showed encouraging results in the pre-clinical and preliminary clinical evaluations [106c].
Cationic, polymer-based delivery systems face limitations due to toxicity, low transfection efficiencies, difficulties in formulation and in vivo stabilization. Efforts in polycation preparation, modification with hydrophilic polymers to increase salt and serum stability, and addition of bioactive functionalities to enhance intracellular trafficking have been discussed by these authors [107] . PEI-graft-poly(ethylene glycol) (PEI-g-PEG) was prepared by grafting linear PEGs onto branched PEIs using hexamethylene diisocyanate (HMDI) in order to activate the monomethyl PEG and to couple it with PEI. These copolymers were soluble in water and their urethane and urea bonds were hydrolytically stable. It was found that PEG reduces the toxicity of PEI and prevents haemolysis as well as the aggregation of erythrocytes. The extent of these positive effects depends on the number of PEG blocks and the structure of block copolymers [108] .
The introduction of cationic 5-(3-aminopropyl)-2'-deoxypyrimidines into duplex DNA induces DNA bending. The presence of the aminopropyl chain induces a decrease in base stacking interactions in the 'modified duplex' and induces a higher exposure of aromatic bases to solvents [109] .
Stabilization of nucleotide hybridization is considered important for improving gene therapy. The comb-type cationic graft copolymers, consisting of a cationic polylysine backbone grafted with polyglucose (dextran) as the hydrophilic side chains, stabilized the triple helical DNA and exerted a considerable accelerating effect on both triple helix formation and strand exchange reactions. It seems that the molecular design of cationic graft copolymers may be a promising strategy for modulation of the inter/ intra-molecular recognition and assembling of polynucleotides [110] .
Prevention of restenosis by the PLG nanospheres, c. 300 nm large, loaded with the partially phosphorothioated oligodeoxynucleotide, a modified growth factor β-receptor antisense (PT-ODN), was investigated in vivo and in vitro. The amount of PT-ODN encapsulated in the nanoparticles could be as high as 81%, and its sustained release was observed. After the initial burst of 13% during the first day, 98% of the remaining PT-ODN was released over a period of one month. The in vivo experiments indicated that the PLG nanospheres loaded with PT-ODN might be a promising gene delivery system for treatment of restenosis [111] .
An angiogenic endothelial cell-targeted polymeric gene delivery carrier was prepared by conjugating an integrin-binding RGD peptide (ACDCRGDCFC) with PEI via a hydrophilic PEG spacer. The PEI-1g-PEG-RGD were homogeneous and their effective diameter was 100 nm to 200 nm. A fivefold increase over PEI was observed for the PEI-1g-PEG-RGD in in vitro transfection experiments with angiogenic endothelial cells [112] .
Tissue engineering
Biocompatible bioresorbable polymers have been used for the preparation of temporary implants, as well as for drug delivery. Surface and/or interface compatibility may be crucial. It has been achieved by an appropriate functionalization of surfaces of biodegradable and non-biodegradable polymers, and by coating metallic devices. The modification of surfaces, binding of adhesion mediators, in order to optimize cell adhesion, and coating by chemical vapour deposition-polymerization has been investigated [17,26,30a] .
Tissue engineers have been tempted initially to engineer virtually every human tissue. However, such tissues as liver, kidney, and other vital organs proved to be too difficult to replicate. On the other hand, engineering of such tissues, as cartilage, bones, and skin, has achieved great success. Potential tissue engineering products may include nerves, muscles, ligaments, heart valves, liver, bladder and vascular grafts. Polymeric systems, such as PGA, PLLA, PLG, poly(N-isopropylacrylamide)-based semi-interpenetrating networks (SIPNs), biodegradable polymeric crosslinked gels, PEG-based block copolymers, functionalized poly(α-hydroxy acids) and associated copolymers, carbohydrate containing polymers, functionalized oligolactide macromers, phospholipid containing polymers, and hybrids combining synthetic polymers with biopolymers have been used for building resorbable scaffolds and other constructs of predetermined shape and size. Several investigators reviewed synthesis, properties and applications of biocompatible and biodegradable polymers suitable for tissue engineering [20b,23d,24] . Relevant concepts and recent investigations related to this subject are briefly discussed in the present review. A scaffold is required as a physical support guiding the formation of a new organ, as well as an adhesive substrate for cells implanted for its generation. Scaffolds should be biocompatible and biodegradable. The three-dimensional structure should be highly porous and the pores should be interconnected. The surface to volume ratio of the pores must be large. Scaffolds should also provide the necessary initial support for the attachment and proliferation of cells, and for the retention of their differentiated functions [113, 114] . The application of peptide-modified electroactive polymers for tissue engineering has also been investigated [114c]. Methods used for the promotion of angiogenesis in the engineered tissues have been discussed [115] .
Photopolymerization can be used in the development of novel biomaterials for tissue engineering [116a] . A photoreactive PVA gel, prepared by converting a few hydroxyl groups of PVA into photopolymerizable groups by reacting them with aminobutyraldehyde diethylacetal, have been investigated for use as scaffolds for tissue engineering. These scaffolds seem to offer several advantages in terms of elastic properties and availability of sites for attachment of bioactive molecules [116b].
Tissue engineering approaches have been clinically tried to repair damaged cartilage. A woven PLLA scaffold was uniformly seeded with collagen-chyndrocyte cells and was subsequently gelled at 37°C. This method could serve as an alternative for in vitro cartilage regeneration [117a] . Chyndrocytes isolated from human ear were seeded on rod shaped biodegradable scaffolds. The seeded scaffolds were maintained in stirred bioreactors for 1 month and implanted subsequently into rats. The implanted rods were flexible, elastic, and were able to withstand a high degree of compressive forces. This technology may be useful for penile reconstruction [117b].
Oligolactide macromers, synthesized by ring-opening oligomerization of lactides and functionalized with methacrylate moieties, have been used as building blocks for the preparation of biocompatible networks. Dimensionally stable, open pore scaffolds were prepared from them by combining the curing and leaching step. Lump sucrose was used as a porogen. The biodegradation behaviour can be changed in a wide range by adding comonomers or various filling materials [118] .
Poly(N-isopropylacrylamide) (PNIPAm)-based semi-interpenetrating networks, containing PNIPAm gel and linear poly(acrylic acid) (PAAc) chains, were synthesized using various lengths of the PAAc chains. PAAc with lower MW was preferred for articular cartilage regeneration, when adhesion between the polymer matrix and the native tissue is desired. However, PAAc with higher MW may be preferred for bone regeneration, when the matrix should function as a bioactive scaffold to promote tissue formation [119] .
Advanced microfabrication techniques, including silicon micromachining and polymer replica molding, have been applied for tissue engineering of complex tissues and organs. Difficulties that have been encountered were due to the lack of an intrinsic blood supply for the tissue-engineered organs, which experienced significant cell death when the thickness of the tissue exceeded the 1 to 2 mm range. Highly resolved biocompatible polymeric tiny scaffolds have been successfully produced by replica molding, from silicon micromachined template wafers. These scaffolds have been successfully seeded with endothelial cells in capillary size channels [120] .
Tissue engineered heart valves, vascular grafts, transplantation of contractile cells or stem cells for myocardial regeneration are not far from their first clinical application. Although the development of an entirely tissue engineered replacement heart is not yet conceivable, it is most likely that tissue engineering strategies will lead to significant improvements in the treatment of acquired and congenital heart disease [121] .
Deep UV irradiation has been claimed to provide a simple, fast, and economical route to obtain chemically patterned polymeric substrates for structural cell adhesion. This method may become a useful tool for the study of a variety of cell cultures and in tissue engineering of bioartificial organs [122a] . Hyperbranched functionalized PAAc thin films (HPFs) have been patterned with micron-scale resolution, using either a template-based approach or photolithography. Grafting a conformal layer of PEG atop HPFs imparts biocompatibility. Such patterns may serve as templates to spatially segregate viable cells [122b].
New tissue-engineered skin substitutes came onto the market during the last two years, and various roles, to which each is best suited, are being resolved [123a] . The artificial skin Integra ® has been developed for the treatment of extensive burn injuries. The interaction of cultured human dermal fibroblasts and epidermal keratinocytes in Integra ® has been investigated. The possibility of replacement of the two stage grafting procedure required by Integra ® by a single-stage grafting was explored [123b].
The fabrication and surface modification of macroporous PLLA and PLG cell scaffolds for artificial skin has been explored. Anhydrous ammonia plasma treatment was used to improve the affinity of the scaffolds towards the fibroblast cells [123c]. The potential for clinical use of poly(hydroxyethyl methacrylate-vinylpyrrolidone) as a delivery vector for the human growth factor has recently been investigated. The rate of polymer and hormone degradation and the proliferation of fibroblast cells were evaluated. It was concluded that this polymer is biodegradable and lacks toxicity towards fibroblast cells. Slow release of the hormone was indicated by the enhancement in cell proliferation. Currently available skin substitutes and their applications for treatment of burns have been reviewed [123d] .
Porous chitin matrices have been used as scaffolds for tissue engineering. They were prepared by freezing and lyophilization of chitin gels cast from a 5% N,N-dimethylacetamide/LiCl solvent system. The pore structure of these matrices was uniform in the micron range. The size depends on the freezing prior to lyophilization. 300 -500 nm pores with an overall porosity of 69% have been produced after freezing with dry ice/acetone. 100 -200 nm pores with an overall porosity of 61% have been obtained after freezing with liquid nitrogen. Smaller then 10 nm pores and overall porosity of 54% has been produced after freezing at -20°C in a freezer for 20 min. These matrices have been found to be non-cytotoxic. It is believed that they hold promise as scaffolds for cell growth and proliferation [124a] . A novel sponge-like material has been formed by solvent casting of PLA blended with biodegradable dextran (D), which was soluble in a (CCl 3 ) 2 /benzene (60/40) mixture. The trimethylsilyl groups protected its hydroxyls. Formation of 100 nm to 200 nm large pores in this material was due to phase separation caused by differences in the solubility of PLA and DTMS in the mixed solvents, and to differences in the rate of evaporation of the two solvents. Scaffolds with less then 10 nm pores were fabricated by dissolving PLA + DTMS in the presence of a salt as a porogen, casting it, subsequent leaching, and removing of protective TMS groups [124b].
Thin PLG films have been used as temporary substrates for the retinal pigment epithelium (RPE) cell culture. The proliferation and differentiation of the RPE cells as well as formation on these films of the desired chemical micropatterns in micrometer scale were discussed. The modulation of the adhesion of the PRE cells by introduction of non-adhesive PEG-PLA domains has been presented [125] .
Tissue engineering in combination with new approaches to cell and gene therapies may create innovative ways for the treatment of tissues of the musculoskeletal system. Principles of muscle-based gene therapy, tissue engineering for the musculoskeletal system, changes in tissue engineering through micro-electro-mechanical systems technology and three-dimensional printing have been reviewed [126a] . The ability to deliver proteins and plasmid DNA over controlled time frames is a challenging problem for tissue engineering. Controlled delivery of proteins and plasmid DNA that provide the capability to change cell function and their influence on gene expression has been investigated [126b].
The use of basic tools of tissue engineering to guide regeneration of diverse tissues, such as cartilage, nerve, small intestines, cardiovascular structures, and liver was discussed. It was pointed out that new, more effective strategies must be developed for the vascularization of complex tissues [127] .
Biomaterials and scaffolds guide the growth of new tissues both in in vitro and in vivo tissue engineering. Analysis of the key cellular processes involved in tissue regeneration has been used for design, better control, and incorporation of new biological moieties into such systems [128] .
In vitro engineering involves handling cells, prior to implantation into the in vivo environment. Cells, biomaterials, and incubation conditions determine the construction of in vitro of systems for the subsequent implantation in vivo. It relies, to a large extent, on the natural ability of the body to regenerate over non-cell-seeded biomaterials. Gene delivery is an important factor controlling link and supporting function of engineered cells in vitro and/or in vivo after implantation. Cell encapsulation, cellseeded constructs, gene delivery, and bioreactors for the in vitro cell engineering have been discussed [129] .
Biodegradable polymers have been used in the surgical treatment of peripheral nerves, but not yet for the central nervous system. It is believed that biodegradable polymer implants with controlled micro-architecture can be engineered and optimized for the implantation in the spinal cord. Implantation could provide a scaffold for axon growth and conduit for delivery of therapeutic agents that may promote axon regeneration. In theory, a biodegradable implant could provide a framework for the growth of axons across spinal cord lesions that could lead to neurological recovery [130] .
Bone repair, regeneration, medication, and implants
Most of recent investigations of topics related to the medication of bones have been dealing with tissue engineering. The use of polymeric materials in a more conventional way has also been the subject of a few investigations. Bioerodible and hydrophobic poly(ortho esters), loaded with appropriate drugs, have been tested on experimental animals, as solid or semi-solid implants, for bone growth and regeneration, and against osteogenesis [17, 26] .
Bone tissue engineering has been heralded as an alternative strategy for the regeneration of bone. The discipline aims to combine progenitor or mature cells with biocompatible materials or scaffolds, with or without growth factor. Though, these strategies are very attractive they have yet to yield functional human bone [131] .
The use of IPNs for bone scaffolds has been mentioned in the previous section (cf. ref. [118] ). PLG has also been found suitable for this purpose [132] . Other polymeric components may include hyaluronic acid gel, as well as polymeric microparticles. A newly isolated osteoblast line [133] has been found to be able to form in vivo within 2 days a new bone matrix that exhibited mature osteoblast phenotype. These cells in combination with PLG-collagen sponge could generate high-density tissue of a predesigned shape (cf. refs. [113b,124b]).
Tissue engineering has also been proposed for the treatment of cartilage defects. Appropriate materials may be manufactured in injectable form, to minimize the invasiveness of the procedures. For large irreparable lesions, an implantation in a preformed state may, however, be required. Its development for treatment of large bone defects would provide attractive alternatives for autografts, allografts, nondegradable polymers, ceramics, or metals that have been currently used in clinical settings [134] .
Photocrosslinking characteristics and material properties of the crosslinked poly-(propylene fumarate) (PPF) for use as an engineered bone graft were investigated: a viscous liquid obtained by dissolving PPF in its monomer, diethyl fumarate (DEF), was photocrosslinked below 47x C with bis(2,4,6-trimethylbenzoyl)phenylphosphine oxide as a photoinitiator. The crosslinkable units were contained within the repeating units of PPF. A low level of heat released by the reaction (less than 160 J/g) was achieved at low levels of UV exposure. Compressive strength of thus prepared materials was similar to that of the human trabecular bone. Elastic modulus and fracture strength of strongest samples were 195.3±17.5 MPa and 69.8±9.4 MPa, respectively. Crosslinking was facilitated at low DEF concentrations, but hindered by its high initial concentrations. It seems that these new materials may be suitable for the tissue engineering of bones [135] .
The transforming growth factor-β1 (TGF-β1) was added to a bioabsorbable selfreinforced poly(L,D-lactic acid) fracture fixation pin. To assess the effect of TGF-β1 on the healing of bone defects, the pins were implanted next to a bone defect filled with a viscose cellulose sponge. A significant increase in the fibroblast-rich mesenchymal tissue inside the viscose cellulose sponge, as well an increase in the amount of new bone on the bone defect were detected after 3 weeks [136] .
Hydroxyapatite (Hap)-biodegradable polymer composites have been prepared by in situ hydrolysis of α-Ca 3 (PO 4 ) 2 in the presence of PLA or PLG at 37°C. Growth of Hap has been completed after 16 h. The total heat evolved during the formation of the Hap composites with PLA or with PLG was 67 kJ/mol HAp and 110 kJ/mol Hap, respectively. The polymer acts as a continuous phase, in which the mineral is dispersed. Such composites combine reasonable mechanical strength with the ability to induce bone growth (osteoconductivity) and the ability to be replaced by the native bone tissue (resorbabilty) [137] . Hydroxyapatite-polysaccharide (micro)granules have been prepared by coprecipitation from sodium alginate and sodium carboxymethylcellulose solutions with the dibasic calcium phosphate hydrate + Ca(OH) 2 as starting materials [138] .
Poly(ε-caprolactone) (ε-PCL) has been proposed, instead of PMMa, as a temporary joint spacer. Particles released by ε-PCL, as result of wear, into joint environments are not cytotoxic, in contradistinction to PMMA. Its wear rates in water and in bovine serum have been found to be comparable to PE and to PTFE, respectively. It seems that wear of ε-PCL in this special application may be acceptable [139] .
Encapsulation matrices for osteoblasts, prepared with PEG hydrogels, modified with the adhesive ARG-GLY-ASP (RGD) peptide sequences, were assessed for applicability in promoting bone tissue engineering. Increase in osteoblast attachment and spreading was observed at high concentration of the RGD groups in the modified PEG. Cytoskeleton organization was observed at highest peptide density only. Significant mineralization was observed in in vivo experiments due to the presence of RGD groups in the network. When gels were formed using 10 wt.-% of a macromer, the majority of the osteoblasts survived the encapsulation process and remained viable after 1 day in the in vitro culture [140] .
Temporary encapsulation in surface crosslinked gelatin microcapsules of marrow stromal osteoblasts (MSO) was investigated. The surface crosslinking of microcapsules produced by exposure, for 5 min, to a 5 mM solution of dithiobis(succinimidylpropionate) (DTSMP) disintegrated in physiological solution after 60 min. The MSO cells, encapsulated in these microcapsules, survived the short crosslinking procedure and retained for 28 days, at a slightly lower level, their proliferative potential and osteoblastic phenotype. These results seem to suggest that temporary encapsulation of MSO cells in gelatine microcapsules may protect them from shortterm environmental effects associated with the crosslinking of an injectable polymeric carrier for bone tissue engineering [141] .
Gentamicin sulfate (GS), an aminoglycoside antibiotic, has been incorporated into the acrylic bone cement to prevent infections. Effects due to the addition of HEMA (2-hydroxyethyl methacrylate) to the liquid component of standard CMW-1 ® bone cement and due to the addition of poly(N-vinyl-2-pyrrolidone) (PVP) to its solid component have been investigated. The addition of HEMA only slightly modifies the amount of released GS. The shape of the release curves is, however, greatly affected. On the other hand, when PVP has been added as a modifier of the hydrophobicity of the matrix, the release rates are greatly increased as a result of formation of channels in the matrix [142] . The polyanhydride implant Septacim TM , containing GS was developed for sustained local delivery of the drug to the site of the infection, for the treatment of osteomyelitis. High local concentration of GS, at the implantation site, may be achieved at lower systemic exposure to the drug. In consequence, undesirable side effects may be reduced [143] . Biodegradable thermoplastic polymers that are able to change their shape after an increase in temperature have recently been described. AB polymer networks have been used. N-butyl acrylate (BA) was used as a comonomer of choice. A switching crystallizable element, based on the oligo(ε-CL) diol component functionalized with polymerizable methacrylate end groups, has been used. The oligo(ε-CL) dimethacrylate crosslinker and the content of BA determine the mechanical properties, switching temperature and the crystallinity [144] . The average M n of oligo(ε-CL) dimethacrylates used were 2000 to 10 000. The crosslinking density was varied by addition of 11 -90 wt.-% and of 20 -71 wt.-% of BA, at the low and high MW of the oligo(ε-CL) dimethacrylate, respectively. All materials reached a constant strain recovery rate of 99% after 3 thermocycles. The shape-memory capability enables bulky implants to be placed in the body through small incisions or to perform automatically mechanical deformations [144c].
Coatings, wound dressing, artificial skin and other organs
Skin tissue engineering concepts based on application of scaffold/cell constructs promise to bring significant therapeutic benefits to the treatment of difficultly healing skin wounds. The so-called bio-dressings contain, besides polymeric materials, products of human or animal origin such cultured skin cells [145, 146] . It has been claimed that the artificial skin Integra® gives satisfactory results. It has been pointed out, however, that the susceptibility to infection, as well as two operations, have been its main problems [147] . Promising results have also been obtained when an artificial skin Tegaderm TM was applied in conjunction with the chemically crosslinked glycosoaminoglycan (GAG). GAG hydrogel films were prepared by attaching adipic dihydrazide to hyaluronan (HA) and to chondromitin sulfate (CS) and crosslinking them with PEGylated propionaldehyde to give a polymer network. GAG hydrogel films provide a highly hydrated environment. The presence of growth and differentiation factors, cell migration, and assembly of other matrix components greatly improves their performance. Wounds treated with either HA or CS films showed more vesicular tissue after 10 days [148a] .
It was claimed that multi-layer polymer films based on PAA complexed with hydroxyethylcellulose might be useful for the controlled release of an antibiotic, levomycetin [148b].
Mechanical properties of fibroin/chitosan blends depend on the ratio between the two components. They have been found to be excellent for blends containing 10 -40% of chitosan. Blends with 40 -50% of chitosan have shown very high permeability to oxygen. The coefficient of their permeability to water vapour increased linearly with the chitosan content. Values of 1000 g/m 2 day to 2000 g/m 2 day were comparable to those of commercial wound dressings [149] .
Porous silk fibroin materials, prepared by freeze-drying, were affected by repeated freeze thawing. When the pore density decreased from 80 to 28 pores per mm 2 , an increase in pore size from 67 -120 nm and in moisture permeability from 230 g/(m 2 ·h) to 308 g/(m 2 ·h) has been observed. At the same time, their compressibility increased from 22.7 to 33.7% [150] .
Modified wound infection preventing 'laminin' membranes, consisting of three phase laminates, have been prepared. The two collagen layers (dense and porous) have been fabricated by air-drying and freeze drying, respectively. Hyaluron (HA) microparticles containing 50 ng/cm 2 of silver sulfadiazine (AgSuDaz) were incorporated into them. The central laminin layer was formed by the liquid coating method. Experiments on animals have shown that lower inflammation, higher vessel proliferation, and wound size reduction have been achieved when these sandwich type, AgSuDaz medicated, collagen membranes were used instead of polyurethane membranes [151a] . HA microparticles containing AgSuDaz were fabricated by gelling the HA solution. The rate of release of AgSuDaz from such could be controlled by UV radiation crosslinking of a membrane [151b] . Polyurethane foams impregnated with HA + AgSuDaz have also been investigated. Apparently, they showed an excellent wound healing effect without any inflammation or yellow cluster [152] .
Chemical vapour deposition polymerization (CVD) may be used for coating implants and other medical devices. CVD-based polymer coating seems to be an attractive method for such purposes. Polymers used may contain functional groups able to conjugate with biomolecules, such as proteins, receptors, or antigens. The required functional groups may also be introduced after a CVD-based coating. The synthesis and the CVD of poly(o-amino-p-xylene-co-p-amino-p-xylene) (amino-ppx) were investigated. The transparent thin films prepared by CVD of amino-ppx showed excellent adhesion to copper substrates and were insoluble in all common solvents. The free primary amino groups on their surface could be used as anchor molecules for further functionalization [153a] . o-Hydroxymethyl-ppx has been prepared as described in ref. [153a] . Anhydride-ppx has been prepared in an analogous fashion from its paracyclophane precursor. The ppx's have been reacted with hexamethylene diisocyanate in order to immobilize r-hirudin on their surface, through hexamethylene leach. The surface bound r-hirudin improved the blood compatibility of coronary stents and devices designed to close intra-arterial communications, as indicated by the decrease in thrombogenicity and reduced adhesion of platelets [153b].
2-Methacryloylphosphorylcholine (MPC) was copolymerized by the free radical technique, using AIBN as initiator, with lauryl methacrylate (LMA), hydroxypropyl methacrylate (HPMA), and with the trimethoxysilylpropyl methacrylate (TMSMA) (cf. Fig. 6a ). The 'one shot' polymerization procedure in ethanol was adopted. Polymerization was continued for 16 h at 62°C. Blocks of PMPC have been formed in the copolymer, since the addition of MPC to itself has been much faster than its addition to the other monomers. The distribution of the other monomers has been, more or less, random. The crosslinking by TMSMA involved partial hydrolysis of its methoxy groups, leading to the creation of Si-O-Si links (cf. Crosslinked PC-based copolymers may be used as coatings to improve the biocompatibility of implants and reduce the levels of adherent bacteria to medical devices. Apparently, they have been used for coating metallic coronary stents (within the framework of the BiodivTsio TM range of stents). Data supporting their safety and efficacy provide evidence that they are biocompatible and should not cause an inflammatory reaction that may be induced by stent placement. Passive bioinertness cannot, however, in itself, exert a profound influence on the biologic processes responsible for restenosis. Local drug delivery strategies must, therefore, be considered to prevent natural negative long-range processes, leading to restenosis. PC-coatings may act as matrix for loading and sustained delivery of the appropriate therapeutics. It has been pointed out that the combination of passive with active coating may effectively reduce the long-term risks of stent-related thrombosis [153e]. A polymeric alloy has been prepared by mixing a 5 wt.-% solution of poly(MPC-co-EHMA) (PMEH) copolymer in ethanol/CH 2 Cl 2 (3:7 v/v) with a 5 wt.-% solution of segmented polyurethane (SPU) in the same solvent. After 30 min of mixing, the mixture has been sonicated for another 30 min, and cast into a dish. Solvent has been evaporated, leaving a polymeric membrane. The membrane was kept for 5 h at room temperature, and at 60°C overnight. It was dried in vacuum at 60°C to completely remove residual solvent. The prepared SPU/PMEH alloy has been compatible with blood and the amount of fibrinogen absorption at its surface decreases with the addition of PMEH. At 10% of PMEH in the alloy, its tensile strength was not much lower than that of SPU. The mechanical strength of SPU depends on the microphase-separated structure of its hard and soft segments. It is dominated by aggregation of the hard segments. Studies conducted on SPU also revealed that the aggregation of hard segments changes significantly as a result of repeated expansion and contraction cycles. DSC measurements have indicated that the structure of SPU in the SPU/PMEH alloy does not change significantly due to temperature changes. This, combined with the blood biocompatibility and low biofouling of this material, suggests that it may be preferable to SPU for the construction of high performance medical devices, such as an artificial heart or implantable catheters [154] .
A slightly different, and possibly more promising, approach to this problem has been proposed by Morimoto et al. [155] . They modified the surface of SPU with PMPC by forming a semi-interpenetrating polymeric network (MS-IPN). To achieve this they prepared SPU films by the solvent evaporation method from 5.0 wt.-% SPU in methanol. They dissolved MPC (30 mol-%), 2-ethylhexyl methacrylate (69.9 mol-%), and triethylene glycol dimethacrylate (0.1 mol-%) in hexafluoroisopropanol (HFIP), to which they added, in the dark, camphorquinone and 4-(N,N-dimethylamino)benzoate (10 -2 mol/l of each). They immersed in the dark the SPU film into this solution for 2 min. Subsequently, they irradiated it in argon with visible light (λ max = 487 nm) for 30 min at 20°C. The MS-sIPN surfaces of the impregnated films have been dried over night in vacuum at 50°C. They had been immersed for 90 min in ethanol, to extract the unreacted monomers and the uncrosslinked polymer, and again dried in vacuum. Studies of platelet adhesion revealed that the MS-sIPN films prevented adhesion. 25 Moreover, after repeated stress loading with 5% strain, at 1 Hz for 25 h at room temperature and pH 7.4, they still behaved in the same way [155] .
